Targets › PTAFR
1 program from 1 company in 3 trials: 1 Phase 1, 1 Phase 3, 1 Phase 2; Genitourinary, Immunology.
Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth-muscle contractile and hypotensive activity. Seems to mediate its action via a G protein that activates a phosphatidylinositol-calcium second messenger system. (UniProt, P25105)
Open in Phaseline: the race on PTAFR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Noucor Health | Rupatadine Platelet activating factor receptor antagonist; Histamine H1 receptor antagonist | PTAFR, HRH1 | Phase 1 | Renal Impairment; Rheumatoid Arthritis; Ulcerative Colitis | – |
Renal Impairment (1) Rheumatoid Arthritis (1) Ulcerative Colitis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.